Grufity logo
Grufity logo
RCEL

RCEL - Avita Medical Ltd Stock Price, Fair Value and News

$10.06-0.03 (-0.30%)
Market Closed as of 21 Aug 2026, 04:00 pm ET

20/100

RCEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

20/100

RCEL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RCEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RCEL Price Action

Last 7 days

28.2%

Last 30 days

103.6%

Last 90 days

119.7%

Trailing 12 Months

111.8%

RCEL RSI Chart

RCEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RCEL Valuation

Market Cap

311.1M

Price/Earnings (Trailing)

-7.22

Price/Sales (Trailing)

4.11

EV/EBITDA

-8.59

Price/Free Cashflow

-12.62

RCEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RCEL Fundamentals

RCEL Revenue

Revenue (TTM)

75.6M

Rev. Growth (Yr)

17.83%

Rev. Growth (Qtr)

12.73%

RCEL Earnings

Earnings (TTM)

-43.1M

Earnings Growth (Yr)

22.75%

Earnings Growth (Qtr)

27.78%

RCEL Profitability

Operating Margin

81.56%

EBT Margin

-56.94%

Return on Equity

154.76%

Return on Assets

-90.17%

Free Cashflow Yield

-7.92%

RCEL Investor Care

Shares Dilution (1Y)

16.21%

Diluted EPS (TTM)

-1.43

Revenue & Growth

How Avita Medical Ltd generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202672.3M75.6M--
202571.7M74.9M72.4M71.6M
202450.7M54.1M60.0M64.3M
202337.4M40.9M45.4M50.1M
202231.8M29.8M31.9M34.4M
202122.8M29.2M31.2M33.0M
202012.8M14.3M16.1M17.9M
20194.3M5.5M8.5M10.7M
2018-929.0K2.1M3.2M
2017-901.4K--
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Avita Medical Ltd

RCEL
AVITA Medical, Inc. operates as a regenerative medicine company in the United States, Australia, Japan, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's skin. Its lead product is RECELL System, a platform technology allows for the preparation and delivery of spray-on skin cells to regenerate natural healthy epidermis, as well as to use in the treatment of acute thermal burns in patients eighteen years and older. AVITA Medical, Inc. has a research agreement with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
 CEO
 WEBSITEavitamedical.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES126

Avita Medical Ltd Frequently Asked Questions

RCEL is the stock ticker symbol of Avita Medical Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Aug 21 2026, market cap of Avita Medical Ltd is 311.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Aug 21 2026, RCEL's PE ratio (Price to Earnings) is -7.22 and Price to Sales (PS) ratio is 4.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RCEL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Avita Medical Ltd has provided 0.037 (multiply by 100 for percentage) rate of return.